Screener
Xeris Biopharma Holdings, Inc. XERS Q2 2026 earnings
Reported August 6, 2026 · Before market open
Revenue$91.0MBeat by $879.0K
EPS-$0.18Miss by $0.19
Revenue estimate$90.1M
EPS estimate$0.01
“The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev's exceptional commercial momentum. The strategic investments we made for Recorlev earlier this year are gaining traction, and we expect their contribution to become increasingly meaningful as we move through the second half of 2026. Additionally, Gvoke delivered solid sequential improvement in line with our expectations, and Keveyis continued to provide a consistent, high-value contribution to our business.”
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$101.6M
EPS estimate$0.02
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Xeris Biopharma Holdings, Inc. report Q2 2026 earnings?
- Xeris Biopharma Holdings, Inc. (XERS) reported Q2 2026 earnings on August 6, 2026 before market open.
- What were Xeris Biopharma Holdings, Inc.'s Q2 2026 revenue and EPS?
- Xeris Biopharma Holdings, Inc. reported revenue of $91.0M and eps of $-0.18 for Q2 2026.
- Did Xeris Biopharma Holdings, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $90.1M by $879.0K. EPS missed the consensus estimate of $0.01 by $0.19.
- How did Xeris Biopharma Holdings, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 27.2% from $71.5M a year earlier and eps declined 1700.0% from $-0.01.
- Where can I find Xeris Biopharma Holdings, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001867096-26-000063) and the 10-Q periodic report (0001867096-26-000065) directly on SEC EDGAR. The filing index links above go to sec.gov.
